billHR7902•Event Thursday, March 12, 2026Analyzed

To provide that the approved application under the Federal Food, Drug, and Cosmetic Act for the drug mifepristone for the purpose of the termination of intrauterine pregnancy is deemed to have been withdrawn, to establish a Federal tort for harm to women caused by chemical abortion drugs, and for other purposes.

Bearish

Impact6/10

Summary

HR 7902, the Safeguarding Women from Chemical Abortion Act, would withdraw FDA approval for mifepristone for pregnancy termination and establish a federal tort for harm from chemical abortion drugs. The bill is in early legislative stages (referred to committee), making near-term market impact low. The direct revenue exposure for Pfizer ($PFE) and Teva ($TEVA) is immaterial to their overall financials.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

1.HR 7902 is an early-stage bill with low near-term passage probability; no market pricing-in
2.Direct revenue impact on Pfizer and Teva from mifepristone withdrawal is financially immaterial
3.Federal tort provision creates marginal litigation exposure but no direct financial metric
4.No funding amounts; bill is purely regulatory with no appropriations
5.Companion bill S 4066 exists but both are in early committee stages

Market Implications

The market has not reacted to this bill. Pfizer trades at $26.48, near the midpoint of its 52-week range ($21.97–$28.75), with a 30-day decline of -2.07%, consistent with broader market trends. Teva at $31.62 is up +10.02% on a 30-day basis, driven by other factors. The absence of price movement confirms investors view this bill as low-probability. HCA Healthcare ($431.92) has dropped -8.36% in 7 days, likely due to unrelated sector dynamics (managed care reimbursement changes or earnings), not this bill. DaVita ($150.07) shows no reaction.

Full Analysis

HR 7902 is an early-stage bill introduced by Rep. Harshbarger (R-TN) on 2026-03-12. It was referred to the House Energy and Commerce and Judiciary committees. A companion bill (S 4066) has been introduced in the Senate and referred to the HELP committee. The bill has 6 cosponsors. The bill's only substantive provision is the withdrawal of FDA approval for mifepristone for termination of intrauterine pregnancy, effective 14 days after enactment. It also creates a federal tort cause of action for harm caused by chemical abortion drugs. There is no funding authorized or appropriated in this bill. It does not allocate any federal dollars. The mechanism is purely regulatory: changing the legal status of an approved drug. The market impact hinges on mifepristone's revenue for manufacturers. Pfizer (branded Mifeprex) and Teva (authorized generic) are the two primary suppliers. Revenue from this indication is immaterial for both companies—Pfizer's total revenue exceeds $50B, Teva's exceeds $15B. The federal tort provision creates marginal litigation risk but no direct revenue loss beyond the drug itself. The presidential executive actions provided are not relevant to this bill. The Apr 18 Executive Order on mental health does not involve mifepristone or abortion drugs. The Apr 20 Presidential Determination under the Defense Production Act is unrelated to pharmaceutical regulation. Real market data shows no meaningful movement related to this bill. Pfizer ($26.48) has been flat to down, Teva ($31.62) slightly up. HCA Healthcare ($431.92) has seen a sharp 7-day decline (-8.36%), likely unrelated to this early-stage legislation. The market is not pricing in any probability of passage for this bill.

Market Impact Score

6/10

Minimal ImpactModerateMajor Market Event

Connected Signals

Matched on shared policy language across AI analyses, with ticker & timing weight

BillStrong LinkBearish

Safeguarding Women from Chemical Abortion Act

Shared: Fda Approval · Mifepristone · Pharmaceutical40% match

3/10

BillStrong LinkBearish

Protecting Americans from Unsafe Drugs Act of 2026

Shared: Pharmaceutical Companies · Legal Liabilities · Pharmaceutical· Both mention $PFE29% match

4/10

BillStrong LinkBearish

To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.

Shared: Pharmaceutical Companies · Teva Pharmaceutical · Pharmaceutical· Both mention $TEVA, $PFE28% match

4/10

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.

$CMPS $MNMD $GHRS $ATAI $CYBN $NUMI

8/10Source